Research Article

Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 4

Cox regression analysis of primary patency.

VariableUnivariate#Multivariate
HR (95% CI) valueATE value

Age (years)1.02 (0.99–1.04)0.208
Gender (F/M)1.01 (0.7–1.77)0.662
BMI0.99 (0.94–1.04)0.59
Smoking (yes/no)1.36 (0.89–2.08)0.155
Hyperlipidemia (yes/no)0.97 (0.55–1.65)0·902
CAD (yes/no)0.95 (0.63–1.42)0.798
Hypertension (yes/no)1.06 (0.66–1.72)0·799
DM (yes/no)1.26 (0.81–1.96)0.306
ESRD (yes/no)1.06 (0.67–1.69)0.805
Rutherford classification (V plus VI/III plus IV)1.46 (0.87–2.46)0.153
hsCRP (mg/L)1.03 (0.99–1.67)0.11.02 (0.98–1.0)0.399
Diabetic neuropathy2.03 (1.34–3.08)0.0010.94 (0.5–1.74)0.824
Ischemia severity
ABI1.26 (0.78–2.02)0.341
Statin treatment (yes/no)0.38 (0.24–0.62)<0.0010.54 (0.33–0.9)0.017
Cilostazol treatment (>3 Ms/≤3 Ms)0.33 (0.22–0.51)<0.0010.46 (0.3–0.72)0.001
Insulin alone (yes/no)2.12 (1.38–3.25)0.0011.6 (0.91–2.81)0.106
Involved leg (L/R)1.18 (0.82–1.7)0.364
Intervention (bypass/stenting)0.61 (0.41–0.92)0.0190.8 (0.52–1.22)0.292
DR/IR0.34 (0.22–0.53)<0.0010.47 (0.29–0.74)0.001

#Multivariate, weighted Cox regression with average treatment effect (ATE), HR, hazard ratio; CI, confidence interval. ABI, ankle brachial index; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; ESRD, end-stage renal disease; DR, direct revascularization; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; IR, indirect revascularization.